Edition:
India

Deinove SA (ALDEI.PA)

ALDEI.PA on Paris Stock Exchange

1.13EUR
2:43pm IST
Change (% chg)

€-0.01 (-0.53%)
Prev Close
€1.14
Open
€1.15
Day's High
€1.15
Day's Low
€1.13
Volume
3,923
Avg. Vol
64,576
52-wk High
€2.77
52-wk Low
€1.06

Latest Key Developments (Source: Significant Developments)

Deinove To Start Phase II Clinical Trial For DNV3837
Thursday, 16 May 2019 

May 16 (Reuters) - Deinove SA ::DEINOVE IS NOW READY TO START PHASE II CLINICAL TRIAL FOR ITS ANTIBIOTIC COMPOUND DNV3837.PRODUCTION OF FIRST COMMERCIAL BATCH OF DNV3837 HAS BEEN SUCCESSFULLY INITIATED.THIS TRIAL WILL BE CONDUCTED AS PART OF AN ACTIVE INVESTIGATIONAL NEW DRUG (IND) AUTHORIZATION AND A RECENTLY UPDATED VERSION OF CLINICAL PROTOCOL.INCLUSION OF FIRST PATIENT IS PLANNED FOR MID-2019.  Full Article

Novel Antibiotics: Deinove Signs Agreement With Institut Pasteur
Tuesday, 9 Apr 2019 

April 9 (Reuters) - DEINOVE SA ::NOVEL ANTIBIOTICS: DEINOVE SIGNS AN AGREEMENT WITH THE INSTITUT PASTEUR TO EXPLORE THE POTENTIAL OF NEW TARGETED STRAINS.  Full Article

Deinove Signs License Option Agreement With Redx Pharma
Thursday, 22 Mar 2018 

March 22 (Reuters) - DEINOVE SA ::DEINOVE EXPANDS ITS INNOVATIVE ANTIBIOTIC PORTFOLIO BY SIGNING A LICENSE OPTION AGREEMENT WITH REDX PHARMA.PROGRAM DEVELOPED BY REDX PHARMA FOCUSES ON A NEW CLASS OF ANTIBIOTICS AIMED AT TREATING MOST LETHAL INFECTIONS.DEINOVE ACQUIRES AN OPTION FOR A LICENSE ON A SERIES OF MOLECULES ABOUT TO ENTER PRECLINICAL DEVELOPMENT..REDX PHARMA ENTRUSTS DEINOVE WITH NEXT STEPS TO OPTIMIZE ITS ANTI-INFECTIVE PROGRAM..  Full Article

Deinove Collaborates With Naicons On Antibiotics Project
Thursday, 8 Mar 2018 

March 8 (Reuters) - DEINOVE SA ::COLLABORATES WITH NAICONS TO DISCOVER NEW ANTIBIOTICS IN THE FRAME OF THE AGIR PROJECT‍​.AS 1ST STEP, WILL HAVE ACCESS TO 400 STRAINS CAREFULLY SELECTED FOR THEIR POTENTIAL.WILL USE ROBOTIC TECHNOLOGY PLATFORM TO DETECT AND CHARACTERIZE ANTIBIOTIC ACTIVITIES OF THESE STRAINS.IN CASE OF DISCOVERY OF STRAIN OF INTEREST, CO MAY ACQUIRE IT EITHER VIA COMMERCIAL LICENSE OR IN FULL OWNERSHIP.POTENTIAL ACQUISITION OF A STRAIN WOULD BE TO INITIATE DEVELOPMENT OF DRUG CANDIDATES.  Full Article

Deinove and Greentech are making progress in the co-development of their cosmetic active ingredient
Monday, 20 Nov 2017 

Nov 20 (Reuters) - Deinove SA ::DEINOVE AND GREENTECH ARE MAKING PROGRESS IN THE CO-DEVELOPMENT OF THEIR COSMETIC ACTIVE INGREDIENT.‍6 PRE-SELECTED STRAINS ARE IN TESTING PHASE TO VALIDATE FINAL CHOICE OF ACTIVE INGREDIENT TO BE MARKETED IN 2018​.‍TECHNOLOGY TRANSFER TO GREENTECH IS UNDERWAY​.‍GREENTECH PLANS TO LAUNCH A FIRST ACTIVE INGREDIENT CO-DEVELOPED WITH DEINOVE IN SPRING OF 2018​.  Full Article

Deinove H1 operating loss widens to 4.8 million euros
Thursday, 28 Sep 2017 

Sept 28 (Reuters) - DEINOVE SA ::HALF-YEAR NET LOSS OF DEINOVE GROUP (COMPOSED OF DEINOVE AND DEINOBIOTICS) STANDS AT -EUR 3.3M.CASH POSITION: +EUR 6.6M AT JUNE 30, 2017 COMPARED TO +EUR 9.3M AT DECEMBER 31, 2016..H1 TOTAL OPERATING REVENUES EUR 140,000 VERSUS EUR 208,000 YEAR AGO.H1 OPERATING LOSS EUR 4.8 MILLION VERSUS LOSS OF EUR 4.2 MILLION YEAR AGO.CAROTENOIDS PROGRAM ENTERS PHASE 2 OF INDUSTRIALIZATION PROCESS.DEINOVE ASSISTED BY PROCESSIUM TO DEFINE AND IMPLEMENT INDUSTRIAL PRODUCTION PROCESS WITH VIEW TO MARKET FIRST BATCHES IN 2018.COLOR2B PROJECT: ON BASIS OF EFFICACY TESTS, ONE OR TWO STRAINS MAY BE SELECTED IN EARLY 2018 FOR INDUSTRIALIZATION STEP.  Full Article